Participants 819 944 4
postmenopausal women with advanced breast carcinoma who had disease progression after receipt of previous endocrine treatment
Participants 1025 1120 4
319 (74.5%) patients in the fulvestrant group and 322 (76.1%) patients in the anastrozole group
